HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis maintains a 'Buy' rating on Celldex Therapeutics (NASDAQ:CLDX) and raises the price target from $73 to $80.
November 06, 2023 | 4:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The 'Buy' rating maintained by HC Wainwright & Co. and the raised price target could potentially boost investor confidence in Celldex Therapeutics.
Analyst ratings and price targets can significantly influence investor sentiment. The maintained 'Buy' rating and increased price target from HC Wainwright & Co. indicates a positive outlook for Celldex Therapeutics, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100